Company Launches Study Of Antibody-Based Drug For COVID-19

The Wall Street Journal (6/1, Loftus, Subscription Publication) reports Eli Lilly launched the first study of its experimental antibody-based drug LY-CoV555, which was derived from the blood of a COVID-19 survivor. Reuters (6/1, Banerjee) reports Eli Lill...